Heart Test Laboratories, Inc., a medical technology company, provides cardiovascular diagnostic devices. The company is headquartered in Southlake, Texas.
| Revenue (TTM) | 4,519 |
| Gross Profit (TTM) | 2,751 |
| EBITDA | $-9.45M |
| Operating Margin | -139957.00% |
| Return on Equity | -1852.00% |
| Return on Assets | -116.40% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.07 |
| Price-to-Book | 70.85 |
| Price-to-Sales (TTM) | 5024.30 |
| EV/Revenue | 5734.06 |
| EV/EBITDA | -0.14 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 10.50% |
| Shares Outstanding | $4.80M |
| Float | $3.62M |
| % Insiders | 15.65% |
| % Institutions | 3.20% |
Volatility is currently expanding
Proposed business combination with Fortitude, a vertically-integrated digital asset mining platform anchored in Zcash, continues to progress, with closing expected in Q4 calendar 2026
Company believes proposed Fortitude Mining Holdings business combination represents a significant value creation opportunity for the Company's shareholders Fiscal 2026 saw the full commercial launch of the MyoVista Insights platform and submission of the MyoVista wavECG device to the FDA for 510(k) clearance
Company believes proposed Fortitude merger represents a significant opportunity for the Company's shareholders; preliminary proxy statement in connection with the Proposed Transaction expected to be filed shortly, with fiscal 2026 earnings release and business update to follow Company believes proposed Fortitude merger represents a significant opportunity for the Company's shareholders; preliminary proxy statement in connection with the Proposed Transaction expected to be filed shortly, with fiscal 2026 earnings release and business update to follow
Patent covers machine-learning models that use ECG data to estimate echocardiogram parameters indicative of diastolic function Patent covers machine-learning models that use ECG data to estimate echocardiogram parameters indicative of diastolic function
Bunkerhill Health's FDA-cleared ECG-EF algorithm for the detection of reduced ejection fraction becomes the first cleared AI-ECG algorithm available through MyoVista Insights, advancing HeartSciences' SaaS-based, recurring-revenue marketplace strategy Bunkerhill Health's FDA-cleared ECG-EF algorithm for the detection of reduced ejection fraction becomes the first cleared AI-ECG algorithm available through MyoVista Insights, advancing HeartSciences' SaaS-based, recurring-revenue marketplace strategy
Agreement follows Cibolo Health's endorsement of MyoVista Insights for its network of 127 independent hospitals and reflects continued commercial momentum for HeartSciences' ECG management platform Agreement follows Cibolo Health's endorsement of MyoVista Insights for its network of 127 independent hospitals and reflects continued commercial momentum for HeartSciences' ECG management platform
Southlake, TX, April 14, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”) a healthcare information technology (“HIT”) company focused on advancing electrocardiography (“ECG” or “EKG”) through the integration of artificial intelligence (“AI”), would like to remind its shareholders to vote ahead of its upcoming Annual Meeting of Shareholders (the “Annual Meeting”) which will be held virtually on Thursday, April 30, 2026, at 10:00 a.m. Eastern Time. All shareholders of record of HeartSciences' outstanding shares of common stock and Series C preferred stock at the close of business on March 6, 2026, are entitled to participate and vote at the Annual Meeting.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on HSCS and any ticker you trade — then tracks every position and per-strategy win rate.
